BR0215403A - Métodos de geração de agentes multivalentes, multiespecìficos de domìnios vh e vl - Google Patents

Métodos de geração de agentes multivalentes, multiespecìficos de domìnios vh e vl

Info

Publication number
BR0215403A
BR0215403A BR0215403-0A BR0215403A BR0215403A BR 0215403 A BR0215403 A BR 0215403A BR 0215403 A BR0215403 A BR 0215403A BR 0215403 A BR0215403 A BR 0215403A
Authority
BR
Brazil
Prior art keywords
binding site
affinity
methods
heterodimers
multivalent
Prior art date
Application number
BR0215403-0A
Other languages
English (en)
Inventor
Edmund Rossi
Chien-Hsing Chang
David Goldenberg
Original Assignee
Immunomedics Inc
Ibc Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, Ibc Pharmaceuticals filed Critical Immunomedics Inc
Publication of BR0215403A publication Critical patent/BR0215403A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS DE GERAçãO DE AGENTES MULTIVALENTES, MULTIESPECìFICOS DE DOMìNIOS V~ H~ E V~ L~". A presente invenção refere-se a proteínas de ligação multivalentes, multiespecíficas, e métodos de gerar estes agentes de domínios V~ H~ e V~ L~. A proteína de ligação tem três ou mais sítios de ligação onde pelo menos um sítio de ligação liga-se com uma porção de hapteno e pelo menos dois sítios de ligação com antígenos alvo. A presente invenção também refere-se a heterodímeros trívalentes, biespecíficos, que têm pelo menos um sítio de ligação com afinidade para moléculas contendo uma porção de histaminasuccinil-glicila (HSG) e pelo menos dois sítios de ligação com afinidade para antígeno carcinoembriónico (CEA), e para heterodímeros trivalentes, triespecíficos, que têm pelo menos um sítio de ligação com afinidade para moléculas contendo uma porção HSG, pelo menos um sítio de ligação com afinidade para CEA, e pelo menos um sítio de ligação tendo afinidade para um DTPA de índio de complexo de metal-quelato. Além disso, esta invenção refere-se a vetores recombinantes úteis para a expressão destes heterodímeros funcionais em um hospedeiro adequado.
BR0215403-0A 2001-12-26 2002-12-26 Métodos de geração de agentes multivalentes, multiespecìficos de domìnios vh e vl BR0215403A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34210301P 2001-12-26 2001-12-26
PCT/US2002/038985 WO2003057829A2 (en) 2001-12-26 2002-12-26 Methods of generating multispecific, multivalent agents from vh and vl domains

Publications (1)

Publication Number Publication Date
BR0215403A true BR0215403A (pt) 2005-05-03

Family

ID=23340336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215403-0A BR0215403A (pt) 2001-12-26 2002-12-26 Métodos de geração de agentes multivalentes, multiespecìficos de domìnios vh e vl

Country Status (12)

Country Link
US (1) US20030162709A1 (pt)
EP (1) EP1468097A4 (pt)
JP (1) JP2005514030A (pt)
KR (1) KR20040091616A (pt)
AU (1) AU2002364531A1 (pt)
BR (1) BR0215403A (pt)
CA (1) CA2471868A1 (pt)
IL (1) IL162732A0 (pt)
MX (1) MXPA04006327A (pt)
PL (1) PL372144A1 (pt)
RU (1) RU2004122702A (pt)
WO (1) WO2003057829A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003033653A2 (en) * 2001-10-15 2003-04-24 Immunomedics, Inc. Affinity enhancement agents
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
PT3483183T (pt) 2002-03-01 2021-06-02 Immunomedics Inc Imunoconjugado compreendendo anticorpos rs7 humanizados
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
CA2514277C (en) * 2003-01-31 2015-01-20 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
CN1326881C (zh) * 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体，其制备方法及用途
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
US9339559B2 (en) 2005-09-09 2016-05-17 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
CA2621763C (en) * 2005-09-09 2021-04-06 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
JP5368798B2 (ja) 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断し処置するための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2518155B1 (en) 2006-08-04 2014-07-23 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
CA2671431C (en) 2006-12-14 2019-03-26 Georgia State University Research Foundation, Inc. Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
EP2257316B1 (en) 2008-04-02 2018-11-07 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2738485A1 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US9956304B2 (en) 2012-06-05 2018-05-01 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
AU2016326449B2 (en) 2015-09-21 2024-10-31 Aptevo Research And Development Llc CD3 binding polypeptides
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
US11571476B2 (en) 2017-12-11 2023-02-07 Taipei Medical University Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382317D1 (de) * 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
DE69334287D1 (de) * 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
AU690528B2 (en) * 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0799244A1 (en) * 1995-10-16 1997-10-08 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
ATE267610T1 (de) * 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
WO1997038102A1 (en) * 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy

Also Published As

Publication number Publication date
WO2003057829A3 (en) 2004-02-26
IL162732A0 (en) 2005-11-20
EP1468097A2 (en) 2004-10-20
AU2002364531A1 (en) 2003-07-24
CA2471868A1 (en) 2003-07-17
EP1468097A4 (en) 2006-01-11
KR20040091616A (ko) 2004-10-28
JP2005514030A (ja) 2005-05-19
MXPA04006327A (es) 2005-07-13
PL372144A1 (en) 2005-07-11
WO2003057829A2 (en) 2003-07-17
US20030162709A1 (en) 2003-08-28
RU2004122702A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
BR0215403A (pt) Métodos de geração de agentes multivalentes, multiespecìficos de domìnios vh e vl
Gelamo et al. Spectroscopic studies on the interaction of bovine (BSA) and human (HSA) serum albumins with ionic surfactants
BR0213303A (pt) Proteìnas de ligação de alvejamento direto
ATE151113T1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
BRPI0410338A (pt) composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ATE541590T1 (de) Modifizierte antikörper-fragmente
DE60115405D1 (de) Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
MA31695B1 (fr) Anticorps humains a affinite elevee pour le facteur de croissance nerveuse humain
EP1864998A3 (en) Binding molecules
NO983042L (no) Fremstilling av hydrokarbongeler fra jernholdige kilder, polykarboksylsyreforbindelser, og valgfrie aminer i kombinasjon med fosfatestre
DE60137356D1 (de) Erweiterter "tethering" ansatz zum schnellen auffinden von liganden
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
BR0212265B1 (pt) Método para a determinação de pelo menos três analitos, composição, kit para a determinação de pelo menos três analitos e uso de pelo menos três parceiros de ligação para a determinação de pelo menos três analitos em uma amostra
DK0935656T3 (da) Hedgehog interagerende proteiner og anvendelser relateret dertil
BR0213284A (pt) agentes de realce de afinidade
ATE319996T1 (de) Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
Sugiyama et al. Evidence for a common high affinity binding site on glutathione S-transferase B for lithocholic acid and bilirubin.
BR9808605A (pt) Processo para a preparação de uma composição asfáltica de classificação aberta, e, uso de uma composição asfáltica
AU2003304419A1 (en) Botulinum neurotoxin b receptors and use thereof
BR0311465A (pt) Novas sequências gdf-9 e gdf-9b (bmp-15) para alteração da função ovariana e da taxa de ovulação de mamìferos
Ma et al. Interaction of a parabolic notch with a generalized singularity
ZA962813B (en) Polypeptides having a functional domain of interest and method of identifying and using same
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2034 DE 29/12/2009.